The potent CLK/DYRK dual inhibitor T-025 was found to induce alternative splicing in breast cancer cells in vitro and in xenograft tumors in vivo; and to inhibit cancer cell proliferation in vitro and tumor growth in vivo. Here, CLK1 is linked to cancer.